1 – 100 of 169
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Associations of modifiable and non-modifiable risk factors with cognitive functions – a prospective, population-based, 17 years follow-up study of 3,229 individuals
(
- Contribution to journal › Article
-
Mark
Effects of time of the day at sampling on CSF and plasma levels of Alzheimer’ disease biomarkers
(
- Contribution to journal › Article
-
Mark
A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings
(
- Contribution to journal › Article
-
Mark
Divergent functional connectivity changes associated with white matter hyperintensities
(
- Contribution to journal › Article
-
Mark
Plasma Biomarker Strategy for Selecting Patients with Alzheimer Disease for Antiamyloid Immunotherapies
(
- Contribution to journal › Article
-
Mark
Highly Accurate Blood Test for Alzheimer's Disease Comparable or Superior to Clinical CSF Tests
2024) In Nature Medicine(
- Contribution to journal › Article
-
Mark
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology
(
- Contribution to journal › Article
-
Mark
Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings
(
- Contribution to journal › Article
-
Mark
Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment
(
- Contribution to journal › Article
-
Mark
Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders : An International, Multicenter Study
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases
(
- Contribution to journal › Article
-
Mark
Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns
(
- Contribution to journal › Article
-
Mark
Interactions between vascular burden and amyloid-β pathology on trajectories of tau accumulation
(
- Contribution to journal › Article
-
Mark
Fixel-Based Analysis Reveals Tau-Related White Matter Changes in Early Stages of Alzheimer’s Disease
(
- Contribution to journal › Article
-
Mark
Medial temporal lobe atrophy patterns in early- versus late-onset amnestic Alzheimer's disease
2024) In bioRxiv : the preprint server for biology(
- Working paper/Preprint › Preprint in preprint archive
-
Mark
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
2024) In JAMA(
- Contribution to journal › Article
-
Mark
Medial temporal lobe atrophy patterns in early-versus late-onset amnestic Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Diffusion weighted magnetic resonance spectroscopy revealed neuronal specific microstructural alterations in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Disease staging of Alzheimer’s disease using a CSF-based biomarker model
2024) In Nature Aging(
- Contribution to journal › Article
-
Mark
Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Plasma N-terminal containing tau fragments (NTA-tau) : a biomarker of tau deposition in Alzheimer’s Disease
(
- Contribution to journal › Article
-
Mark
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms
(
- Contribution to journal › Article
- 2023
-
Mark
DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease
(
- Contribution to journal › Article
-
Mark
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases
(
- Contribution to journal › Article
-
Mark
Effects of Brain Pathologies on Spatiotemporal Gait Parameters in Patients with Mild Cognitive Impairment
(
- Contribution to journal › Article
-
Mark
Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
(
- Contribution to journal › Article
-
Mark
Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms
(
- Contribution to journal › Article
-
Mark
Measures of cortical microstructure are linked to amyloid pathology in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
An accurate fully automated panel of plasma biomarkers for Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Higher plasma β-synuclein indicates early synaptic degeneration in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia
(
- Contribution to journal › Article
-
Mark
Cognitive effects of Lewy body pathology in clinically unimpaired individuals
(
- Contribution to journal › Article
-
Mark
Clinical effects of Lewy body pathology in cognitively impaired individuals
(
- Contribution to journal › Article
-
Mark
Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes
(
- Contribution to journal › Article
-
Mark
Age-related and amyloid-beta-independent tau deposition and its downstream effects
(
- Contribution to journal › Article
-
Mark
Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
(
- Contribution to journal › Article
-
Mark
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients
(
- Contribution to journal › Article
-
Mark
The genetic regulation of protein expression in cerebrospinal fluid
(
- Contribution to journal › Article
-
Mark
Clinical performance and robustness evaluation of plasma amyloid-β42/40 prescreening
(
- Contribution to journal › Article
-
Mark
Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models
(
- Contribution to journal › Article
-
Mark
Association Between Dietary Habits in Midlife With Dementia Incidence Over a 20-Year Period
(
- Contribution to journal › Article
-
Mark
Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers
(
- Contribution to journal › Article
-
Mark
CSF ferritin in the clinicopathological progression of Alzheimer's disease and associations with APOE and inflammation biomarkers
(
- Contribution to journal › Article
-
Mark
Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes
(
- Contribution to journal › Article
-
Mark
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
(
- Contribution to journal › Article
-
Mark
Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients : A multi-cohort study
(
- Contribution to journal › Article
-
Mark
CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
(
- Contribution to journal › Article
- 2022
-
Mark
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau
(
- Contribution to journal › Article
-
Mark
Complementary pre-screening strategies to uncover hidden prodromal and mild Alzheimer's disease : Results from the MOPEAD project
(
- Contribution to journal › Article
-
Mark
Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD) : A Report of an International Research Collaboration Network
(
- Contribution to journal › Scientific review
-
Mark
Prenatal Gyrification Pattern Affects Age at Onset in Frontotemporal Dementia
(
- Contribution to journal › Article
-
Mark
Association of β-Amyloid Accumulation with Executive Function in Adults with Unimpaired Cognition
(
- Contribution to journal › Article
-
Mark
Components of gait in people with and without mild cognitive impairment
(
- Contribution to journal › Article
-
Mark
The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders
(
- Contribution to journal › Article
-
Mark
Association of CSF Aβ38Levels with Risk of Alzheimer Disease-Related Decline
(
- Contribution to journal › Article
-
Mark
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
(
- Contribution to journal › Article
-
Mark
Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology
(
- Contribution to journal › Article
-
Mark
Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy
(
- Contribution to journal › Article
-
Mark
β-Amyloid-Dependent and-Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Astrocytic function is associated with both amyloid-β and tau pathology in non-demented APOE 4 carriers
(
- Contribution to journal › Article
-
Mark
The protective gene dose effect of the APOE ε2 allele on gray matter volume in cognitively unimpaired individuals
(
- Contribution to journal › Article
-
Mark
Amyloid-associated increases in soluble tau is a key driver in accumulation of tau aggregates and cognitive decline in early Alzheimer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
(
- Contribution to journal › Article
-
Mark
Hippocampal subregional thinning related to tau pathology in early stages of Alzheimer’s disease
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Age-related tau-PET uptake and its downstream effects extend beyond the medial temporal lobe in cognitively normal older adults
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
A biomarker profile of elevated CSF p-tau with normal tau PET is associated with increased tau accumulation rates on PET in early Alzheimer’s disease
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The mean diffusion propagator model revealed cortical microstructural changes associated with both amyloid-β and tau pathology and astroglial activation
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages : Implications for Clinical Alzheimer Trials
(
- Contribution to journal › Article
-
Mark
Prevalence and Ascertainment of Dementia Cases in the Malmö Diet and Cancer Study
(
- Contribution to journal › Article
-
Mark
Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults : Effects of Alzheimer's Disease Pathology and Cognitive Decline
(
- Contribution to journal › Article
-
Mark
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Spatial Navigation and Its Association with Biomarkers and Future Dementia in Memory Clinic Patients Without Dementia
(
- Contribution to journal › Article
- 2021
-
Mark
Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects
(
- Contribution to journal › Article
-
Mark
Comparing the Clinical Utility and Diagnostic Performance of Cerebrospinal Fluid P-Tau181, P-Tau217 and P-Tau231 Assays
(
- Contribution to journal › Article
-
Mark
Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
(
- Contribution to journal › Article
-
Mark
Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Alzheimer’s disease in primary care : new tools for improved and simplified diagnostics
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Genetic influence during the early phases of Alzheimer's disease on longitudinal cognitive impairment
(
- Contribution to journal › Article
-
Mark
Genetic interaction study of Alzheimer's disease quantitative biomarkers : A polygenic risk score analysis and evaluation
(
- Contribution to journal › Article
-
Mark
Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid, tau, and cognition
(
- Contribution to journal › Article
-
Mark
General practitioners’ attitude toward early and pre-dementia diagnosis of ad in five European countries—a mopead project survey
(
- Contribution to journal › Article
-
Mark
A multicentre validation study of the diagnostic value of plasma neurofilament light
(
- Contribution to journal › Article
-
Mark
Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE ε4, sex and age
(
- Contribution to journal › Article
-
Mark
Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers
(
- Contribution to journal › Article
-
Mark
Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments—EQ-5D data from the Swedish BioFINDER study
(
- Contribution to journal › Article
-
Mark
Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
(
- Contribution to journal › Article
-
Mark
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures
(
- Contribution to journal › Article
-
Mark
The effects of tau, amyloid and white matter lesions on mobility, dual tasking and balance in older people
(
- Contribution to journal › Article
-
Mark
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations
(
- Contribution to journal › Article
-
Mark
Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Associations of Plasma Phospho-Tau217 Levels with Tau Positron Emission Tomography in Early Alzheimer Disease
(
- Contribution to journal › Article